Suven Pharmaceuticals acquires 56% stake in NJ Bio

21 Dec 2024 Evaluate

Suven Pharmaceuticals has acquired 56% equity share capital of NJ Bio, Inc., at an aggregate consideration of $64.4 million, which includes $15 million of primary equity infusion into the NJ Bio. Therefore, the acquisition of 56% equity share capital of NJ Bio by the company has been completed on December 20, 2024.

Suven Pharmaceuticals is India’s leading technology-focused CDMO, offering integrated solutions in custom synthesis, process R&D, and manufacturing for global innovators.


Cohance Lifesciences Share Price

383.85 -2.70 (-0.70%)
23-Jan-2026 10:13 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1630.85
Dr. Reddys Lab 1243.00
Cipla 1377.90
Zydus Lifesciences 891.45
Lupin 2154.50
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×